Jiejin Qian1, Xianbo Huang1, Yinyin Zhang1,2, Xiujin Ye1, Wenbin Qian1,2. 1. Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China. 2. Malignant Lymphoma Diagnosis and Therapy Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China.
Abstract
BACKGROUND: Canonical Wnt/β-catenin signaling is frequently dysregulated in acute myeloid leukemia (AML) and has been implicated in leukemogenesis. γ-catenin was previously demonstrated to be associated with the nuclear localization of β-catenin, the central mediator, and to exert oncogenic effects in AML; however, the underlying mechanisms remain unclear. Our study aimed to investigate the expression characteristics of γ-catenin in AML patients, explore the mechanisms by which γ-catenin regulates β-catenin, and discuss the feasibility of targeting γ-catenin for AML treatment. METHODS: The mRNA expression levels of γ-catenin in AML patients were measured by qRT-PCR. Cell proliferation was examined via Cell Counting Kit-8 (CCK-8) assays. The expression levels of related proteins were measured via Western blotting. Specific siRNA was used to modulate the expression level of the γ-catenin gene. Apoptosis and cell cycle distribution were quantified by flow cytometry. The subcellular localization of γ-catenin and β-catenin was examined via immunofluorescence with a confocal laser scanning microscope. RESULTS: Overexpression of γ-catenin was frequently observed in AML and correlated with poor prognosis. Consistent with this finding, suppression of γ-catenin in the AML cell line THP-1 induced growth inhibition, promoted apoptosis and blocked β-catenin nuclear translocation. Interestingly, γ-catenin knockdown sensitized THP-1 cells to cytotoxic chemotherapeutic agents such as cytarabine and homoharringtonine and further inhibited β-catenin nuclear localization. Moreover, our data implied the relationship between γ-catenin and GSK3β (whose effect on β-catenin is mediated by its own phosphorylation), which may be the principal mechanism underlying the anti-AML effect of γ-catenin inhibition. CONCLUSION: Taken together, our results revealed a potential role of γ-catenin in AML pathogenesis-mainly through the inhibition of GSK3β-mediated nuclear localization of β-catenin-and indicate that targeting γ-catenin might offer new AML treatments.
BACKGROUND: Canonical Wnt/β-catenin signaling is frequently dysregulated in acute myeloid leukemia (AML) and has been implicated in leukemogenesis. γ-catenin was previously demonstrated to be associated with the nuclear localization of β-catenin, the central mediator, and to exert oncogenic effects in AML; however, the underlying mechanisms remain unclear. Our study aimed to investigate the expression characteristics of γ-catenin in AML patients, explore the mechanisms by which γ-catenin regulates β-catenin, and discuss the feasibility of targeting γ-catenin for AML treatment. METHODS: The mRNA expression levels of γ-catenin in AML patients were measured by qRT-PCR. Cell proliferation was examined via Cell Counting Kit-8 (CCK-8) assays. The expression levels of related proteins were measured via Western blotting. Specific siRNA was used to modulate the expression level of the γ-catenin gene. Apoptosis and cell cycle distribution were quantified by flow cytometry. The subcellular localization of γ-catenin and β-catenin was examined via immunofluorescence with a confocal laser scanning microscope. RESULTS: Overexpression of γ-catenin was frequently observed in AML and correlated with poor prognosis. Consistent with this finding, suppression of γ-catenin in the AML cell line THP-1 induced growth inhibition, promoted apoptosis and blocked β-catenin nuclear translocation. Interestingly, γ-catenin knockdown sensitized THP-1 cells to cytotoxic chemotherapeutic agents such as cytarabine and homoharringtonine and further inhibited β-catenin nuclear localization. Moreover, our data implied the relationship between γ-catenin and GSK3β (whose effect on β-catenin is mediated by its own phosphorylation), which may be the principal mechanism underlying the anti-AML effect of γ-catenin inhibition. CONCLUSION: Taken together, our results revealed a potential role of γ-catenin in AML pathogenesis-mainly through the inhibition of GSK3β-mediated nuclear localization of β-catenin-and indicate that targeting γ-catenin might offer new AML treatments.
Authors: Elizabeth A Griffiths; Michelle C Golding; Pragya Srivastava; Benjamin J Povinelli; Smitha R James; Laurie A Ford; Meir Wetzler; Eunice S Wang; Michael J Nemeth Journal: Haematologica Date: 2014-11-07 Impact factor: 9.941
Authors: Linus Angenendt; Christoph Röllig; Pau Montesinos; David Martínez-Cuadrón; Eva Barragan; Raimundo García; Carmen Botella; Pilar Martínez; Farhad Ravandi; Tapan Kadia; Hagop M Kantarjian; Jorge Cortes; Gunnar Juliusson; Vladimir Lazarevic; Martin Höglund; Sören Lehmann; Christian Recher; Arnaud Pigneux; Sarah Bertoli; Pierre-Yves Dumas; Hervé Dombret; Claude Preudhomme; Jean-Baptiste Micol; Christine Terré; Zdeněk Ráčil; Jan Novák; Pavel Žák; Andrew H Wei; Ing S Tiong; Meaghan Wall; Elihu Estey; Carole Shaw; Rita Exeler; Lisa Wagenführ; Friedrich Stölzel; Christian Thiede; Matthias Stelljes; Georg Lenz; Jan-Henrik Mikesch; Hubert Serve; Gerhard Ehninger; Wolfgang E Berdel; Michael Kramer; Utz Krug; Christoph Schliemann Journal: J Clin Oncol Date: 2019-08-20 Impact factor: 44.544
Authors: Carsten Müller-Tidow; Björn Steffen; Thomas Cauvet; Lara Tickenbrock; Ping Ji; Sven Diederichs; Bülent Sargin; Gabriele Köhler; Matthias Stelljes; Elena Puccetti; Martin Ruthardt; Sven deVos; Scott W Hiebert; H Phillip Koeffler; Wolfgang E Berdel; Hubert Serve Journal: Mol Cell Biol Date: 2004-04 Impact factor: 4.272
Authors: W Fiskus; S Sharma; S Saha; B Shah; S G T Devaraj; B Sun; S Horrigan; C Leveque; Y Zu; S Iyer; K N Bhalla Journal: Leukemia Date: 2014-12-08 Impact factor: 11.528